Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Brain Diseases × enzalutamide × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 74 Breast Neoplasms 9 Metastatic Castration Resistant Prostate Cancer 8 Neoplasms 7 Neoplasm Metastasis 7 Prostatic Neoplasms, Castration-Resistant 6 Prostate Cancer Metastatic 4 Castration-resistant Prostate Cancer 3 Triple Negative Breast Neoplasms 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Non-metastatic Castration-resistant Prostate Cancer 2 Metastatic Castration-resistant Prostate Cancer 2 Metastatic Castration-Resistant Prostate Cancer 2 Urinary Bladder Neoplasms 1 Urinary Bladder Diseases 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Ureteral Diseases 1 Seizures 1 Recurrent Endometrial Endometrioid Adenocarcinoma 1 Prostate Carcinoma Metastatic to the Bone 1 Primary Dysautonomias 1 Primary Breast Cancer ER+ve 1 Pharmacokinetics of MDV3100 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Metastatic Progressive Castration-resistant Prostate Cancer 1 Metastatic Hormone Sensitive Prostate Cancer 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Kidney Diseases 1

Interventions

Cancer Vaccines 2 Adjuvants, Immunologic 2 veliparib 1 glutathione pegylated liposomal doxorubicin 1 enzalutamide 1 Trastuzumab 1 Radiosurgery 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04290611 2023-04-13

VENDY

Groupe Hospitalier Pitie-Salpetriere

500,000 enrolled

Brain Diseases, Epilepsy, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡